Tarlatamab治疗SCLC中肿瘤炎症相关神经毒性模拟重度ICANS一例
本文报告一例伴有多个脑转移及症状性癫痫史的年轻女性SCLC患者,在接受第四线tarlatamab首次1 mg剂量后27小时出现突发意识丧失(ICE评分0)与癫痫发作,符合4级神经毒性标准。影像示脑转移灶增大伴瘤周水肿加重,脑电图见肿瘤部位局灶性癫痫样放电,强化糖皮质激素治疗后36小时内症状迅速缓解。作者将该事件判定为局部肿瘤炎症驱动的TIAN而非ICANS,提示TIAN可表现为严重但可逆、酷似高级别ICANS的神经毒性。
要点
- tarlatamab首剂1 mg后27小时出现4级神经毒性,需警惕TIAN可能
- 影像见脑转移灶增大伴瘤周水肿加重、脑电图见肿瘤部位局灶癫痫样放电支持TIAN
- 强化糖皮质激素后36小时内迅速缓解,TIAN可与ICANS鉴别并可能支持谨慎继续治疗
核心结论
- 伴脑转移的SCLC患者接受tarlatamab后可出现由局部肿瘤炎症驱动的TIAN,表现酷似高级别ICANS但严重而可逆。
- 区分TIAN与ICANS至关重要,因TIAN可能可控,识别后可在密切监测下个体化决定是否继续治疗。
研究设计与样本
- 单例病例报告,来源于J Thorac Oncol,报告一例接受tarlatamab第四线治疗的SCLC年轻女性患者。
- 患者伴多个脑转移及症状性癫痫史,接受tarlatamab首次1 mg剂量后发生严重神经毒性事件。
主要发现
- 首剂1 mg tarlatamab后27小时突发意识丧失(ICE评分0)并出现癫痫发作,符合4级神经毒性标准。
- 脑影像示脑转移灶增大伴瘤周水肿加重,脑电图示肿瘤部位局灶性癫痫样放电。
- 强化糖皮质激素治疗后症状在36小时内迅速缓解,后续谨慎继续tarlatamab未见严重神经毒性复发,复查影像示肿瘤明显退缩。
关键数值与推荐
- 神经毒性分级按4级判定(ICE评分0);症状缓解时间为36小时内;tarlatamab首剂剂量为1 mg。
- 事件判定为肿瘤炎症驱动的TIAN而非ICANS,依据为影像瘤周水肿加重与脑电图肿瘤部位局灶癫痫样放电。
临床怎么用
- 对伴脑转移的SCLC患者使用tarlatamab时,应警惕严重急性神经毒性可能为TIAN而非ICANS。
- 出现类似高级别ICANS表现时应结合脑影像与脑电图评估瘤周炎症,强化糖皮质激素可能迅速缓解。
- TIAN识别后可在密切监测下个体化考虑继续tarlatamab治疗。
局限性
- 仅为单例病例报告,结论的外推性有限。
- TIAN与该场景下的判定缺乏统一标准,需更多病例与数据验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tarlatamab, a delta-like ligand 3-targeting bispecific T-cell engager, has demonstrated promising efficacy in relapsed SCLC. Data on immune effector cell-associated neurotoxicity syndrome (ICANS) in patients with central nervous system disease remain limited. In particular, tumor inflammation-associated neurotoxicity (TIAN), proposed in chimeric antigen receptor T-cell therapy as localized neurotoxicity linked to peritumoral inflammation, has not been characterized in this setting. CASE PRESENTATION: Here, we describe a single case of severe neurotoxicity in a young woman with SCLC and multiple brain metastases who had a history of symptomatic epilepsy and received tarlatamab as fourth-line therapy. She developed sudden loss of consciousness (immune effector cell-associated encephalopathy score: 0) and seizures 27 hours after the initial 1 mg dose of tarlatamab. The patient's presentation met the criteria for grade 4 neurotoxicity. Brain imaging revealed enlarged brain metastases with worsened peritumoral edema, and electroencephalography demonstrated focal epileptiform discharges at the tumor site. The symptoms resolved rapidly (within 36 h) after intensified corticosteroid therapy. Tarlatamab was cautiously continued without recurrence of severe neurotoxicity, and subsequent imaging revealed marked tumor regression. The event was interpreted as TIAN driven by local tumor inflammation rather than ICANS. CONCLUSIONS: Severe acute neurotoxicity may indicate TIAN in patients with SCLC and brain metastases treated with tarlatamab. TIAN presents as severe but reversible symptoms that mimic high-grade ICANS. Differentiating TIAN from ICANS is crucial because TIAN may be manageable, and its recognition may inform individualized decisions regarding therapy continuation under careful monitoring.
引用
- Torasawa M, Shukuya T, Huang J, et al. Tumor Inflammation-Associated Neurotoxicity Masquerading as Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report. J Thorac Oncol. 2026. PMID: 41848463. doi:10.1016/j.jtho.2026.103649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。